Barry Borlaug, MD
Advanced Heart Failure and Transplant Cardiology · Rochester, MNNPI 1518975374
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $164,792 of the $173,452 with a category attached, or 95.0%. 13 manufacturers reported payments, led by Eli Lilly at 31.4% of the total. Reporting peaked in 2024 at $52,405 and has fallen 53.8% since, to $24,190 in 2025. Among advanced heart failure and transplant cardiology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $1734.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$55K
- Merck$29K
- Boehringer Ingelheim International GmbH$25K
- Novo Nordisk AS$22K
- Edwards Lifesciences$11K
- Janssen Research & Development, LLC$11K
- plus $21K from 7 others
Across 220 payments — averaging $8146.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.2M
- Novo Nordisk$491K
- Novo Nordisk AS$133K
- Sensible Medical Innovations Ltd$15K
- Eli Lilly$713
What the payments were for
- Consulting fees$164,79295%
- Speaking & faculty fees$8,5925%
- Food & beverage$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 47 | $54,525 |
| Merck | 8 | $29,241 |
| Boehringer Ingelheim International GmbH | 12 | $25,009 |
| Novo Nordisk AS | 8 | $22,253 |
| Edwards Lifesciences | 9 | $10,934 |
| Janssen Research & Development, LLC | 2 | $10,875 |
| Regeneron | 4 | $4,956 |
| Abbott | 5 | $4,200 |
| Novartis | 1 | $3,960 |
| Amgen | 1 | $2,975 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $2,275 |
| Biotronik Inc. | 1 | $1,600 |
| Bard Peripheral Vascular, Inc. | 1 | $650 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$19,505
- MOUNJARO$5,600
- CardioMEMS HF System$4,200
How this compares
$173,452 in reported general payments places this provider in the 95th percentile of 32 advanced heart failure and transplant cardiology providers in Minnesota.
See all advanced heart failure and transplant cardiology providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 11 | $6,094 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Rochester
- Robert FrantzRochester$141K
- Omar AbouezzeddineRochester$10K
- Swaiman SinghRochester$9K
- Dipan UppalRochester$4K
- Naveen PereiraRochester$3K
- Farris TimimiRochester$3K
- Rosalyn AdigunRochester$2K
- Atta BehfarRochester$2K
- Arindam SharmaRochester$2K
- Alfredo ClavellRochester$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.